Akebia Therapeutics, Inc. (AKBA) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease. The company operates with two commercial products: Vafseo (vadadustat), launched in the U.S. in January 2025 for anemia in dialysis patients, and Auryxia (ferric citrate), which lost exclusivity in the U.S. in March 2025. The company maintains a pipeline of mid-stage assets (praliciguat, AKB-097) and early-stage HIF molecules.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $236.2 million | $160.2 million | +47% |
| Net Product Revenue | $227.3 million | $152.2 million | +49% |
| Net Loss | $(5.3) million | $(69.4) million | Improvement of $64.1M |
| Operating Income | $23.5 million | $(50.5) million | Turnaround to Profit |
| Cash and Equivalents | $184.8 million | $51.9 million | +256% |
| Accumulated Deficit | $(1.68) billion | $(1.68) billion | N/A |
Revenue Breakdown: Vafseo generated $45.8 million in its first full year of U.S. sales. Auryxia generated $181.5 million, including sales of an authorized generic version following loss of exclusivity (LoE).
Debt and Liquidity: The company holds a $55.0 million senior secured term loan facility with BlackRock (maturity Jan 2028). As of Dec 31, 2025, the company had $184.8 million in cash, sufficient to fund operations for at least two years.
Material Changes vs. Prior Period
- Profitability Turnaround: The company moved from a net loss of $69.4 million in 2024 to a net loss of $5.3 million in 2025, driven by a 47% revenue increase and the cessation of amortization on the Auryxia intangible asset (fully amortized in 2024).
- Vafseo Launch: Vafseo entered the U.S. market in January 2025, contributing $45.8 million in revenue. Approximately 290,000 dialysis patients have prescribing access.
- Auryxia Loss of Exclusivity: Auryxia lost exclusivity in March 2025. An authorized generic is now sold by Mylan. Teva received tentative FDA approval for a generic version in January 2026, signaling increased competition in 2026.
- Acquisition: In November 2025, Akebia acquired AKB-097 (a complement inhibitor) from Q32 Bio for an upfront payment of $7.0 million plus potential milestones totaling up to $582 million. This resulted in a $12.8 million charge to R&D expense.
- Capital Raising: The company raised approximately $66.4 million in net proceeds from equity sales in 2025 (underwritten offering and ATM facility).
Guidance, Outlook, and Risks
Outlook: Management believes current cash resources and expected revenues are sufficient to fund operations for at least two years. The strategic focus remains on driving Vafseo to become the standard of care for anemia in dialysis patients and advancing the rare kidney disease pipeline.
Key Risks and Contingencies:
- Generic Competition: Additional generic versions of Auryxia are expected to enter the market in 2026, which is expected to adversely impact revenue. The impact depends on pricing and the company's ability to maintain contracts with dialysis organizations.
- Reimbursement: Both Auryxia and Vafseo are included in the Medicare ESRD Prospective Payment System (PPS) bundle. They currently receive Transitional Drug Add-on Payment Adjustment (TDAPA) payments. Post-TDAPA (after 2026 for Auryxia, 2027 for Vafseo), reimbursement will rely on base rate adjustments, creating uncertainty regarding profitability.
- Debt Covenants: The BlackRock Credit Agreement requires maintaining either $15.0 million in cash or $150.0 million in trailing twelve-month revenue. Failure to meet these covenants could trigger an event of default.
- Regulatory: The company is not pursuing the broad label expansion for Vafseo in non-dialysis patients (VALOR trial) following FDA feedback, though it remains open to smaller subpopulations.
- Supply Chain: The company relies on single-source suppliers for Auryxia and Vafseo drug substance and product, including manufacturers in China (WuXi STA), creating exposure to geopolitical and trade risks.
Investor Verification Checklist
- Auryxia Revenue Trajectory: Verify the rate of revenue decline for Auryxia in 2026 as additional generic competitors (beyond the authorized generic) enter the market.
- Vafseo Adoption Rates: Monitor the number of dialysis organizations implementing Vafseo protocols and the conversion rate from injectable ESAs to Vafseo.
- Reimbursement Policy Changes: Track legislative developments regarding the Kidney Care Access Protection Act (KCAPA) and CMS decisions on post-TDAPA base rate adjustments for the ESRD bundle.
- Debt Covenant Compliance: Confirm monthly compliance with the BlackRock Credit Agreement covenants (cash balance vs. revenue threshold).
- Pipeline Milestones: Watch for data readouts from the praliciguat Phase 2 trial (FSGS) and the initiation of the AKB-097 Phase 2 basket study in late 2026.
- Manufacturing Risks: Assess the impact of U.S.-China trade tensions on the supply chain, specifically regarding WuXi STA (Vafseo drug substance) and Patheon (drug product).